Document Detail

Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study.
MedLine Citation:
PMID:  20885298     Owner:  NLM     Status:  In-Process    
The objective of the present study was to evaluate the efficacy, safety and healthcare resource utilization of long-term treatment with tinzaparin in symptomatic patients with acute pulmonary embolism as compared to standard therapy. In this open-label trial, 102 patients with objectively confirmed pulmonary embolism were randomized to receive, after initial treatment with tinzaparin, either tinzaparin (175 IU/kg/day) or international normalized ratio-adjusted acenocoumarol for 6 months. Clinical endpoints were assessed during the 6 months of treatment. A pharmacoeconomic analysis was carried out to evaluate the cost of the long-term treatment with tinzaparin in comparison with the standard one. In an intention-to-treat analysis, one of 52 patients developed recurrent venous thromboembolism in the tinzaparin group compared with none of the 50 patients in the acenocoumarol group. One patient in each group had a major haemorrhagic complication. Six patients in the acenocoumarol group had minor bleeding compared with none in the tinzaparin group (P = 0.027). Median hospital length of stay was shorter in the tinzaparin group compared to the acenocoumarol group (7 versus 9 days; P = 0.014). When all the direct and indirect cost components were combined for the entire population, we found a slight, nonstatistically significant (mean difference €345; 95% CI 1382-2071; P = 0.69) reduction in total cost with tinzaparin. Symptomatic acute pulmonary embolism treatment with full therapeutic doses of tinzaparin for 6 months is a feasible alternative to conventional treatment with vitamin K antagonists.
Luis A Pérez-de-Llano; Virginia Leiro-Fernández; Rafael Golpe; Jose M Núñez-Delgado; Ana Palacios-Bartolomé; Lidia Méndez-Marote; Esteve Colomé-Nafria
Related Documents :
23447648 - Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in parkin...
11417988 - (131)i-mibg radionuclide therapy is safe and cost-effective in the control of symptoms ...
20875048 - Economic evaluation of vacuum assisted closure® therapy for the treatment of diabetic f...
16690578 - A preliminary economic evaluation of percutaneous neuromuscular electrical stimulation ...
11549478 - Comparison of outcomes of ureteroscopy for ureteral calculi located above and below the...
19660368 - A comparison before and after aprotinin was suspended in cardiac surgery: different res...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis     Volume:  21     ISSN:  1473-5733     ISO Abbreviation:  Blood Coagul. Fibrinolysis     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-02     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9102551     Medline TA:  Blood Coagul Fibrinolysis     Country:  England    
Other Details:
Languages:  eng     Pagination:  744-9     Citation Subset:  IM    
Pneumology Service, Hospital Xeral-Calde, Lugo, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Targeted ultrasound is the procedure of choice for detecting rudimentary branchial cysts causing jug...
Next Document:  Arteriovenous differences of hematological and coagulation parameters in patients with sepsis.